Targeted IgMs agonize ocular targets with extended vitreal exposure

Area of Science:

• Ophthalmology
• Immunology
• Drug Delivery

Background:

• The blood-retinal barrier limits drug efficacy for ocular diseases.
• Current intravitreal injections require frequent administration, burdening patients.
• Under-treatment is common due to dosing challenges.

Purpose of the Study:

• To investigate Immunoglobulin M (IgM) as a novel therapeutic platform for ocular diseases.
• To assess the suitability of IgMs for ocular administration and their therapeutic potential.

Main Methods:

• Evaluation of IgM properties for ocular delivery (viscosity, exposure, clearance).
• Modification of IgMs to remove complement-dependent cytotoxicity (P436G mutation).
• Assessment of IgM-mediated activation of Tie2 and death receptor 4 pathways.

Main Results:

• IgMs demonstrate suitable viscosity, long ocular exposure, and rapid systemic clearance.
• A P436G mutation effectively reduced IgM-related safety concerns.
• Dodecavalent IgM binding potently activated Tie2 and death receptor 4 pathways.

Conclusions:

• IgMs are a promising platform for ocular drug delivery.
• Modified IgMs can be safely administered and effectively target pathways for treating progressive blindness.
• IgMs represent potential therapeutic agonists for conditions like diabetic macular edema and wet age-related macular degeneration.